Skip to main content
PTC THERAPEUTICS, INC. logo

PTC THERAPEUTICS, INC. — Investor Relations & Filings

Ticker · PTCT ISIN · US69366J2006 LEI · 549300UJLWOIWFDGB318 US Manufacturing
Open in API
Filings indexed 1,162 across all filing types
Latest filing 2017-11-02 Earnings Release
Country US United States of America
Listing US PTCT

About PTC THERAPEUTICS, INC.

https://www.ptcbio.com/

PTC Therapeutics, Inc. is a global biopharmaceutical company that discovers, develops, and commercializes clinically differentiated medicines for children and adults with rare and serious diseases. The company focuses on conditions with high unmet medical needs, leveraging its expertise across multiple scientific platforms. These platforms include RNA biology, with a focus on splicing modification to control protein production, and targeting inflammation and ferroptosis pathways for central nervous system diseases. PTC has brought several pioneering treatments to market, including the first approved therapy for Duchenne muscular dystrophy, the first gene therapy administered directly into the brain, and the first small molecule splicing modifier. The company maintains a diversified pipeline of innovative therapies.

Recent filings

Filing Released Lang Actions
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filing with the SEC, dated November 2, 2017, reporting the financial results for the quarter ended September 30, 2017. It includes a press release as an exhibit announcing quarterly financial results. The text explicitly states it is a current report on Form 8-K and the content is a financial results announcement for a quarter, which aligns with an Earnings Release. The document length is 3416 characters, which is relatively short and typical for an earnings release announcement rather than a full interim report. Therefore, the document is best classified as an Earnings Release (ER).
2017-11-02 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce significant events. The text mentions an 'Other Events' section describing a press release about receiving a Complete Response letter from the FDA regarding a New Drug Application. The document is short (2967 characters) and primarily serves to announce this event and attach the press release as an exhibit. There are no financial statements or detailed financial data included. This fits the profile of a Regulatory Filing (RNS) as it is a general regulatory announcement and does not fit into more specific categories like Annual Report, Earnings Release, or Legal Proceedings Report. Therefore, the appropriate classification is Regulatory Filings (RNS).
2017-10-25 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce unscheduled material events or corporate changes. The content describes an event related to the FDA advisory committee meeting and the voting results on a drug treatment, which is an 'Other Event' disclosure. The document is short (3334 characters) and does not contain financial statements or detailed financial analysis. It is not an annual or quarterly report, nor a call transcript or management report. It is a regulatory announcement of a material event, fitting the category of Regulatory Filings (RNS).
2017-09-28 English
8-K
Board/Management Information Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated September 18, 2017, reporting the departure of a board member and appointment of a consulting agreement. The key section is Item 5.02, which relates to changes in directors or officers. There is no financial data or report attached, and the document is relatively short (3934 characters). This matches the definition of Board/Management Information (MANG), which covers announcements of changes in the company's board of directors or senior management. Therefore, the document should be classified as MANG with high confidence.
2017-09-18 English
Regulatory Filings 2017
Regulatory Filings
2017-08-30 English
S-3ASR
Capital/Financing Update Classification · 100% confidence The document is a Form S-3 registration statement filed with the SEC by PTC Therapeutics, Inc. It is a registration statement under the Securities Act of 1933 used for registering securities to be offered to the public. The text includes a prospectus describing the general terms of securities offerings, including debt securities, common stock, preferred stock, depositary shares, purchase contracts, purchase units, and warrants. It discusses the shelf registration process allowing the company to sell securities from time to time in one or more offerings. The document is not a financial report, earnings release, or management discussion, but rather a capital markets filing related to securities issuance and registration. Therefore, it fits the category of Capital/Financing Update (CAP).
2017-08-24 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.